Latest Insider Transactions at Akero Therapeutics, Inc. (AKRO)
This section provides a real-time view of insider transactions for Akero Therapeutics, Inc. (AKRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,800
-2.09%
|
$117,800
$31.1 P/Share
|
|
Dec 17
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+2.04%
|
$72,200
$19.87 P/Share
|
|
Dec 16
2024
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+9.63%
|
-
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,074
-8.66%
|
$263,146
$29.11 P/Share
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,074
+7.97%
|
$190,554
$21.1 P/Share
|
|
Dec 16
2024
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+20.26%
|
-
|
|
Dec 16
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
1,000
-2.84%
|
$29,000
$29.13 P/Share
|
|
Dec 16
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
17,400
+33.04%
|
-
|
|
Dec 16
2024
|
Scott A. Gangloff Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+50.0%
|
-
|
|
Dec 16
2024
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,300
+27.95%
|
-
|
|
Dec 16
2024
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,500
+12.4%
|
-
|
|
Dec 16
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+9.16%
|
-
|
|
Dec 10
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,818
-1.33%
|
$144,540
$30.91 P/Share
|
|
Dec 10
2024
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,450
+1.34%
|
$46,550
$19.87 P/Share
|
|
Dec 10
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,503
-1.21%
|
$75,090
$30.79 P/Share
|
|
Dec 10
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
7,855
-1.3%
|
$235,650
$30.79 P/Share
|
|
Dec 10
2024
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,817
-6.85%
|
$84,510
$30.79 P/Share
|
|
Dec 10
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,810
-3.79%
|
$84,300
$30.79 P/Share
|
|
Dec 10
2024
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
925
-4.92%
|
$27,750
$30.79 P/Share
|
|
Dec 02
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.62%
|
$320,000
$32.13 P/Share
|
|
Dec 02
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-3.97%
|
$800,000
$32.09 P/Share
|
|
Dec 02
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+3.81%
|
$525,000
$21.1 P/Share
|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,061
-5.47%
|
$253,708
$28.26 P/Share
|
|
Nov 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,061
+9.82%
|
$190,281
$21.1 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-11.88%
|
$350,000
$35.19 P/Share
|
|
Nov 06
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.62%
|
$0
$0.62 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
108,366
-8.06%
|
$3,359,346
$31.99 P/Share
|
|
Nov 01
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,366
+7.35%
|
$2,275,686
$21.1 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,716
-6.63%
|
$1,622,912
$32.15 P/Share
|
|
Nov 01
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,716
+13.23%
|
$855,036
$21.09 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,485
-17.27%
|
$495,520
$32.62 P/Share
|
|
Nov 01
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,485
+14.73%
|
$325,185
$21.1 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,515
-5.74%
|
$144,480
$32.53 P/Share
|
|
Oct 30
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,515
+5.43%
|
$94,815
$21.1 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
63,539
-4.75%
|
$1,969,709
$31.83 P/Share
|
|
Oct 18
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
63,539
+8.67%
|
$1,334,319
$21.1 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
3,103
-0.51%
|
$96,193
$31.12 P/Share
|
|
Oct 17
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,103
+0.51%
|
$65,163
$21.1 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
24,992
-3.96%
|
$774,752
$31.14 P/Share
|
|
Oct 16
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+3.81%
|
$524,832
$21.1 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14,825
-8.26%
|
$444,750
$30.72 P/Share
|
|
Oct 15
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,825
+14.13%
|
$0
$0.62 P/Share
|
|
Oct 14
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,136
-7.64%
|
$184,080
$30.03 P/Share
|
|
Oct 14
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.86%
|
$0
$0.62 P/Share
|
|
Oct 14
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
40,000
-15.02%
|
$1,200,000
$30.15 P/Share
|
|
Oct 14
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+13.06%
|
$840,000
$21.09 P/Share
|
|
Oct 01
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.23%
|
$280,000
$28.18 P/Share
|
|
Sep 20
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,500
-6.81%
|
$148,500
$27.65 P/Share
|
|
Sep 20
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+6.37%
|
$0
$0.62 P/Share
|
|
Sep 18
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,871
-4.89%
|
$104,517
$27.56 P/Share
|